Related Experiment Videos
Inotropic agents in the treatment of heart failure: despair or hope?
1Department of Cardiovascular Medicine, Kyoto University, Japan.
Abstract:
Depression of myocardial contractility plays an important role in the development of heart failure; therefore, intensive interest and passion have been generated to develop cardiotonic agents to improve the contractile function of the failing heart. Inotropic agents that increase cyclic AMP, either by increasing its synthesis or reducing its degradation, exert dramatic short-term hemodynamic benefits, but these acute effects cannot be extrapolated into long-term improvement of the clinical outcome in patients with advanced heart failure. Administration of these agents to an energy-starved failing heart would be expected to increase myocardial energy use and could accelerate disease progression. The role of digitalis in the management of heart failure has been controversial, but ironically the drug has now been proved to favorably affect the neurohormonal disorders and its reevaluation is now being intensively investigated. More recently, attention has been focused on other inotropic agents that have a complex and diversified mechanism. Recent clinical studies have demonstrated that they are potentially useful in the long-term treatment of heart failure patients. These agents have some phosphodiesterase-inhibitory action but also possess additional effects, including acting as cytokine inhibitors, immunomodulators, or calcium sensitizers. However, their therapeutic ratio is narrow and further studies are warranted to establish their optimal doses and their eventual status in the treatment of heart failure.
Insights
New cardiotonic agents show promise for heart failure treatment by improving contractility. While traditional agents offer short-term benefits, newer drugs with diverse mechanisms may provide long-term clinical improvement.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Myocardial contractility depression is central to heart failure development.
- Traditional inotropic agents (e.g., those increasing cyclic AMP) provide short-term hemodynamic benefits but not long-term clinical improvement in advanced heart failure.
- These agents may increase myocardial energy demand, potentially worsening disease progression.
Purpose of the Study:
- To review the evolving landscape of cardiotonic agents for heart failure.
- To explore the mechanisms and potential of novel inotropic agents beyond traditional cyclic AMP-based therapies.
- To discuss the reevaluation of digitalis and emerging agents with complex mechanisms.
Main Methods:
- Literature review and analysis of current clinical studies on heart failure pharmacotherapy.
- Examination of the mechanisms of action for various inotropic agents, including phosphodiesterase inhibitors, cytokine inhibitors, immunomodulators, and calcium sensitizers.
- Discussion of the clinical outcomes and therapeutic ratios of these agents.
Main Results:
- Traditional inotropic agents targeting cyclic AMP have limitations for long-term heart failure management.
- Digitalis is undergoing reevaluation for its neurohormonal effects in heart failure.
- Novel agents with phosphodiesterase-inhibitory and other multifaceted actions show potential for long-term treatment, despite narrow therapeutic ratios.
Conclusions:
- Newer inotropic agents with complex mechanisms offer potential for long-term heart failure treatment.
- Further research is essential to determine optimal dosing and definitive roles for these agents.
- The therapeutic landscape for heart failure is evolving beyond traditional inotropic support.